Filipa Lynce, Md

This study tests a new drug called azenosertib combined with two standard chemotherapy drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal is to find the safest dose and see if the combination shrinks tumors. About 78 adults wit…